The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLPE.L Regulatory News (SLPE)

  • There is currently no data for SLPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Quarterly Investment Update at 30 June 2020

30 Sep 2020 07:00

RNS Number : 4793A
Standard Life Private Eqty Trst PLC
30 September 2020
 

Standard Life Private Equity Trust plc

Legal Entity Identifier (LEI): 2138004MK7VPTZ99EV13

 

1. Investment update for the quarter ended 30 June 2020

 

· The net asset value ("NAV") per ordinary share of Standard Life Private Equity Trust plc ("the Company") increased by 11.1% to 473.9 pence for the quarter ended 30 June 2020

· Realised gains and income on the portfolio during the quarter ended 30 June 2020 totalled £18.2 million (2.8% of NAV). The unrealised gain on a constant exchange rate basis was £46.3 million (7.1% of NAV). In addition, there were unrealised foreign exchange gains of £14.8 million (2.2% of NAV)

· The first interim dividend for the financial year ending 30 September 2020 of 3.3 pence per share was paid on 24 April 2020

· 100.0% by value of the portfolio was valued by the respective underlying managers at 30 June 2020

· NAV total return was 11.9% for the three months from 1 April 2020 to 30 June 2020

· Outstanding commitments were £465.5 million at 30 June 2020

· Cash and cash equivalents were £52.0 million at 30 June 2020

 

For the quarter ended 30 June 2020, the Company's NAV increased by 11.1% to 473.9 pence per share from 426.4 pence per share at 31 March 2020. At 30 June 2020, the Company's net assets were £728.6 million (31 March 2020 - £655.6 million). NAV total return was 11.9% for the three months from 1 April 2020 to 30 June 2020.

 

The closing value of the Company's portfolio, which included 63 private equity interests, was £660.9 million at 30 June 2020 (31 March 2020 - £580.3 million and 62 private equity interests). 100.0% by value of the portfolio valuations were dated 30 June 2020. The valuations by the underlying managers as at 30 June 2020 have not been adjusted by the Manager.

 

The total unrealised gain on the portfolio for the quarter ended 30 June 2020 was £61.1 million (9.3%), comprising £46.3 million (7.1%) of unrealised gain on a constant exchange rate basis and £14.8 million (2.2%) of unrealised foreign exchange gains. The capital movement of the FTSE All-Share Index (in sterling) was + 9.8% during the quarter. The unrealised foreign exchange gains were driven by the Euro and the US Dollar appreciating by 2.7% and 0.4% respectively relative to sterling over the quarter.

 

During the quarter ended 30 June 2020, the portfolio generated £30.0 million of distributions (quarter ended 31 March 2020 - £64.6 million). The Company funded £31.2 million of drawdowns (quarter ended 31 March 2020 - £44.0 million) into the portfolio. The portfolio distributions received during the quarter generated £18.2 million (2.8%) of net realised gains and income. This was equivalent to a return of 2.5 times the acquisition cost of the realised investments.

 

The Company made a new primary commitment during the quarter of €25.0 million to Vitruvian IV. The Company had total outstanding commitments to its 63 private equity interests of £465.5 million at 30 June 2020 (31 March 2020 - £451.2 million to 62 private equity interests). The Manager believes that around £68.3 million of the Company's outstanding commitments at 30 June 2020 are unlikely to be drawn.

 

The Company had cash and cash equivalents of £52.0 million at 30 June 2020 (31 March 2020 - £59.6 million). In addition, it is due £15.5 million (31 March 2020 - £15.2 million) of deferred consideration during the year from investments sold in 2019. The Company also had an undrawn £100.0 million syndicated revolving credit facility provided by Citi and Societe Generale, expiring in December 2024.

 

 

2. Activity since 30 June 2020

 

On 31 July 2020, the Company paid the second interim dividend for the year ending 30 September 2020 of 3.3 pence per ordinary share. The cost of the dividend was £4.9 million. In addition, the Company declared a third quarter dividend for the year ending 30 September 2020 of 3.3 pence per ordinary share, to be paid on 30 October, to shareholders on the Company's share register as at 25 September 2020.

 

During the period from 1 July 2020 to 14 September 2020 the Company received £16.4 million of distributions and funded £18.4 million of drawdowns and co-investment funding.

 

In August 2020, the Company made a $7.0 million co-investment into Visma, a leading provider of mission critical enterprise resource planning software in the Nordics and the Netherlands. The co-investment was made alongside Hg, Visma's lead investor.

 

The Company had cash and cash equivalents of £43.1 million at 14 September 2020. In addition, it is due £15.5 million of deferred consideration during the year from investments sold in 2019. The Company also had total outstanding commitments of £440.1 million. The Manager believes that around £66.3 million of the Company's outstanding commitments are unlikely to be drawn.

 

In September 2020, the syndicated revolving credit facility was expanded to £200.0 million from £100.0 million. This expansion of the existing facility includes the introduction of State Street Bank International as a new lender to the Company alongside long-term lenders Citi and Societe Generale. The expiry date of the facility remains as December 2024.

 

 

3. Update on COVID-19

 

The Manager continues to be mindful of the impact of COVID-19 and maintains regular communication with the private equity managers of the Company's investments. Whilst the Company's NAV has recovered strongly this quarter following a decline of 8.2% in Company NAV in March, the Manager remains cautious in respect of the valuation of the Company's portfolio in the coming quarters.

 

An update from the Manager, which provides responses to frequently asked questions in relation to COVID-19, is available within the Latest News section of the Company website; www.slpet.co.uk.

 

 

4. Future Announcements

 

The Company's estimated NAV at 31 August 2020 is also being announced today. The Company is expecting to announce its estimated NAV at 30 September 2020 on 14 October 2020.

 

It is anticipated that the Company will release its results for the year ending 30 September 2020 on or around 25 January 2021.

 

For further information please contact:-

 

Alan Gauld at SL Capital Partners LLP (0131 528 4424)

 

Note:-

Standard Life Private Equity Trust PLC is an investment company managed by SL Capital Partners LLP, the ordinary shares of which are admitted to listing by the UK Listing Authority and to trading on the Stock Exchange and which seeks to conduct its affairs so as to qualify as an investment trust under sections 1158-1165 of the Corporation Tax Act 2010. The Board of Standard Life Private Equity Trust PLC is independent of Standard Life Aberdeen plc and Phoenix Group Holdings.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUKASRRUUKUAR
Date   Source Headline
12th Feb 20217:00 amRNSEstimated NAV at 31 January 2021
5th Feb 202112:17 pmRNSDoc re. Annual Report
2nd Feb 20215:28 pmRNSDirector/PDMR Shareholding
26th Jan 20217:05 amRNSEstimated NAV at 31 December 2020
26th Jan 20217:00 amRNSAnnual Financial Report
5th Jan 20214:00 pmRNSQuarterly disclosure
22nd Dec 20204:30 pmRNSREPLACEMENT: Dividend Declaration
14th Dec 20203:01 pmRNSEstimated NAV at 30 November
14th Dec 20203:01 pmRNSFourth Interim Dividend
13th Nov 20207:00 amRNSEstimated NAV at 31 October 2020
12th Nov 20203:26 pmRNSDirector/PDMR Shareholding
5th Nov 20208:31 amRNSEdison review on Standard Life Private Equity Trst
3rd Nov 202012:33 pmRNSDirector/PDMR Shareholding
3rd Nov 20207:02 amRNSDirector Declaration
14th Oct 20207:00 amRNSEstimated NAV at 30 September 2020
2nd Oct 20204:28 pmRNSQuarterly disclosure
30th Sep 20207:02 amRNSEstimate Net Asset Value at 31 August 2020
30th Sep 20207:00 amRNSQuarterly Investment Update at 30 June 2020
24th Sep 20207:00 amRNSIncrease of Loan Facility
8th Sep 202012:21 pmRNSEdison review on Standard Life Private Equity Trst
3rd Sep 202011:08 amRNSThird Interim Dividend
14th Aug 20207:00 amRNSEstimated NAV at 31 July 2020
13th Aug 202010:20 amRNSDirector/PDMR Shareholding
6th Aug 20203:04 pmRNSDirector/PDMR Shareholding
15th Jul 20202:10 pmRNSUpdate research from QuotedData
14th Jul 20207:00 amRNSEstimated NAV at 30 June 2020
2nd Jul 20204:43 pmRNSQuarterly disclosure
26th Jun 20207:00 amRNSHalf-Yearly Report
18th Jun 20207:05 amRNSEstimated NAV at 31 May 2020
18th Jun 20207:00 amRNSHalf-year Report
15th May 20207:00 amRNSEstimated Net Asset Value at 30 April 2020
12th May 20204:07 pmRNSHolding(s) in Company
11th May 202012:14 pmRNSGlobal Macro Review – May 2020
28th Apr 20204:20 pmRNSDisclosure of Rights Attaching to Equity Shares
28th Apr 20203:35 pmRNSDirector/PDMR Shareholding
28th Apr 202011:52 amRNSDirector/PDMR Shareholding
24th Apr 20207:02 amRNSEstimated Net Asset Value at 31 March 2020
24th Apr 20207:00 amRNSQuarterly Investment Update at 31 December 2019
3rd Apr 202010:22 amRNSQuarterly Disclosure
13th Mar 20207:00 amRNSMonth End Net Asset Value(s)
11th Mar 20201:59 pmRNSReal Estate Roundup Review – March 2020
9th Mar 20209:52 amRNSDirector Declaration
9th Mar 20207:00 amRNSFirst Interim Dividend
24th Feb 20203:20 pmRNSResult of AGM
14th Feb 20207:00 amRNSMonth End Net Asset Value(s)
13th Feb 202012:37 pmRNSReplacement - Director/PDMR Shareholding
13th Feb 202012:16 pmRNSDirector/PDMR Shareholding
12th Feb 20202:55 pmRNSDirector/PDMR Shareholding
29th Jan 20208:13 amRNSEdison review on Standard Life Private Equity
28th Jan 20204:31 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.